Epithelial-mesenchymal Transition

Epithelial-mesenchymal transition (EMT) and its reverse, mesenchymal-epithelial transition (MET) are developmental programs which have been shown to play critical roles in promoting metastasis and invasion as well as contribute to drug resistance in carcinoma. ATCC has employed CRISPR/Cas9 gene editing to develop its first reporter line designed to enable the real-time monitoring of the changing status of cells from epithelial to mesenchymal. 


  • CRISPR/Cas9 gene-edited vimentin-RFP fusion protein
  • Strong RFP signal upon vimentin induction
  • Physiological E-cadherin expression in the absence of EMT
  • TGFβ1-responsive
  • Increased invasive capacity following EMT
  • EMT sensitive to A83-01 and PP1 inhibition
    • Fluorescence-labeled EMT Reporter

      Validation of A549-Vim-RFP

      Upon EMT induction, the EMT reporter cell line undergoes morphological changes from epithelial to mesenchymal, along with increased expression of Vim-RFP. Learn more about how ATCC created and validated these advanced EMT models from the flyer.

      Lung EMT Reporter

      Vim-RFP-A549 Cell Line

      By utilizing the CRISPR/Cas9 gene editing, ATCC offers an advanced EMT model of lung carcinoma. This cell line serves ideal in vitro model for metastasis studies and anti-cancer drug screening.

      Related Products

      A549 cells
      DMEM:F12K Medium
      Fetal Bovine Serum

      ATCC can provide the basal culture medium and serum that you need to grow your EMT cells. We also carry the parental A549 cell line.